For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Intravitreal Ranibizumab 2.0mg | Initial dose 2.0mg switched to 1.0mg at near conclusion of study. ranibizumab 2.0mg: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections | None | None | 0 | 3 | 2 | 3 | View |
| Observation | Observation; No treatment given | None | None | 0 | 3 | 2 | 3 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Sinusitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | None | View |
| Cold | SYSTEMATIC_ASSESSMENT | Immune system disorders | None | View |
| Food Poisoning | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Diabetes | SYSTEMATIC_ASSESSMENT | Endocrine disorders | None | View |
| Elevated Blood Pressure | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Ear Infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | None | View |
| Allergies | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |
| Stiff Neck | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | None | View |